NYSE:DGX - Quest Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$114.06 -0.32 (-0.28 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$114.38
Today's Range$113.75 - $114.73
52-Week Range$90.10 - $116.49
Volume543,300 shs
Average Volume984,068 shs
Market Capitalization$15.61 billion
P/E Ratio21.10
Dividend Yield1.74%
Quest Diagnostics logoQuest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryHealth Care Services


Debt-to-Equity Ratio0.73
Current Ratio1.23
Quick Ratio1.14


Trailing P/E Ratio21.10
Forward P/E Ratio17.26
P/E Growth2.27

Sales & Book Value

Annual Sales$7.71 billion
Price / Sales2.01
Cash Flow$7.3303 per share
Price / Cash15.56
Book Value$36.35 per share
Price / Book3.14


EPS (Most Recent Fiscal Year)$5.40
Net Income$772 million
Net Margins10.19%
Return on Equity15.44%
Return on Assets7.23%


Outstanding Shares135,820,000
Market Cap$15,612.16

The Truth About Cryptocurrencies

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Monday, May 14th. Stockholders of record on Monday, July 9th will be paid a dividend of $0.50 per share on Monday, July 23rd. This represents a $2.00 annualized dividend and a dividend yield of 1.75%. The ex-dividend date is Friday, July 6th. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its board has initiated a stock buyback plan on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 7.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings results on Thursday, April, 19th. The medical research company reported $1.52 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $1.52. The medical research company earned $1.88 billion during the quarter, compared to the consensus estimate of $1.89 billion. Quest Diagnostics had a net margin of 10.19% and a return on equity of 15.44%. The company's quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter last year, the company posted $1.33 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY18 earnings guidance on Thursday, April, 19th. The company provided EPS guidance of $6.50-6.70 for the period, compared to the Thomson Reuters consensus estimate of $6.60. The company issued revenue guidance of $7.70-7.77 billion, compared to the consensus revenue estimate of $7.72 billion.

What price target have analysts set for DGX?

21 analysts have issued 12 month price targets for Quest Diagnostics' stock. Their forecasts range from $86.00 to $130.00. On average, they anticipate Quest Diagnostics' stock price to reach $110.1765 in the next twelve months. This suggests that the stock has a possible downside of 3.4%. View Analyst Ratings for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 10 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 43)

Has Quest Diagnostics been receiving favorable news coverage?

News coverage about DGX stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quest Diagnostics earned a media sentiment score of 0.14 on Accern's scale. They also assigned news stories about the medical research company an impact score of 45.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.20%), NN Investment Partners Holdings N.V. (0.18%), State of Alaska Department of Revenue (0.14%), Gateway Investment Advisers LLC (0.08%), Denali Advisors LLC (0.07%) and Retirement Systems of Alabama (0.05%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, John B Ziegler, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Acropolis Investment Management LLC, CenturyLink Investment Management Co, Retirement Systems of Alabama and Gateway Investment Advisers LLC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Mitsubishi UFJ Asset Management UK Ltd., Manning & Napier Group LLC, Denali Advisors LLC, NN Investment Partners Holdings N.V., Calamos Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund and Investment House LLC. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $114.06.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $15.61 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  606 (Vote Underperform)
Total Votes:  938
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.